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ARTICLE
Predictive impact of rare genomic copy number
variations in siblings of individuals with autism
spectrum disorders
L. D’Abate1,2, S. Walker1, R.K.C. Yuen 1,2, K. Tammimies 1,3,4, J.A. Buchanan1, R.W. Davies1,
B. Thiruvahindrapuram1, J. Wei1, J. Brian5, S.E. Bryson6, K. Dobkins7, J. Howe1, R. Landa8, J. Leef5, D. Messinger9,
S. Ozonoff10, I.M. Smith6, W.L. Stone11, Z.E. Warren12, G. Young10, L. Zwaigenbaum13 & S.W. Scherer1,2,14*
Identification of genetic biomarkers associated with autism spectrum disorders (ASDs) could
improve recurrence prediction for families with a child with ASD. Here, we describe clinical
microarray findings for 253 longitudinally phenotyped ASD families from the Baby Siblings
Research Consortium (BSRC), encompassing 288 infant siblings. By age 3, 103 siblings
(35.8%) were diagnosed with ASD and 54 (18.8%) were developing atypically. Thirteen
siblings have copy number variants (CNVs) involving ASD-relevant genes: 6 with ASD, 5
atypically developing, and 2 typically developing. Within these families, an ASD-related CNV
in a sibling has a positive predictive value (PPV) for ASD or atypical development of 0.83; the
Simons Simplex Collection of ASD families shows similar PPVs. Polygenic risk analyses
suggest that common genetic variants may also contribute to ASD. CNV findings would have
been pre-symptomatically predictive of ASD or atypical development in 11 (7%) of the 157
BSRC siblings who were eventually diagnosed clinically.
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Behavioral assessments remain the gold standard for autismspectrum disorder (ASD) diagnosis1, and prospectiveanalysis permits objective and longitudinal assessment for
the earliest symptoms. Published estimates of sibling recurrence
for ASD range from 6.9 to 19.5%2–5. Moreover, of younger
siblings of autistic probands, herein referred to simply as
“infant siblings”, who are not diagnosed with ASD, up to
30–40% have subclinical ASD traits and/or suboptimal devel-
opmental functioning6.
ASD and related subclinical traits show familial clustering, with
a substantial portion of familial liability attributed to genetic
factors7,8. Subclinical symptoms in first- and second-degree rela-
tives support an important role for genetic factors in producing an
autistic phenotype9. The genetic architecture of ASD is being
resolved by studying families with different characteristics10–21,
and dozens of copy number variant (CNV) loci and ASD-relevant
genes and loci are known, many of which overlap those associated
with other neurodevelopmental disorders14,17,18. De novo and
inherited rare (<1% in a population) CNVs and other pathogenic
variants are found in ~ 5–40% of individuals with ASD, depending
on the cohort examined10,14,17,20. Chromosomal microarray to
detect CNVs is the first-tier laboratory test for clinical genetic
evaluation following an ASD diagnosis22.
The most effective way to reduce symptoms of ASD is with
early intervention, targeting behavior, and skills develop-
ment23. In search of biomarkers for early indentification, we
investigated whether CNVs affecting ASD-related loci correlate
(pre- and post-symptomatically) with phenotypic outcomes in
the Baby Siblings Research Consortium (BSRC) cohort of
infant siblings whose family history is associated with a higher
probability of developing ASD (Fig. 1). We analyze CNVs
from 253 families registered in the BSRC24 while blinded to
the infant siblings’ phenotype status. At enrollment, each
family included a proband diagnosed with ASD, and at least 1
younger sibling (Supplementary Table 1). The BSRC long-
itudinal phenotyping design enables a predictive study of
CNVs in this infant cohort (see Methods). Our analyses
reveal that the detection of ASD-relevant CNVs is indeed
predictive of ASD or atypical development in this sibling
population and can be used to inform risk estimates for indi-
viduals and their families, with potential impact on their
therapeutic trajectory.
Results
Clinical evaluation of infant siblings within families. The study
group included the 253 probands, 288 later-born infant siblings
comprising the primary diagnostic sample (Fig. 1), and 34 sib-
lings who did not meet cohort enrollment criteria (i.e., >3 years,
or status determined only through parental reports), but for
whom we had phenotype designation and genotype data. Refer to
“Subject recruitment and clinical evaluations” in Methods section
for criteria for various atypical outcomes listed below. At age 3,
103/288 siblings (35.8%) in 94/253 families (37.2%) had a formal
diagnosis of ASD; 54 were “atypically developing” (18.8%), and
131 were developing typically (45.5%) (Supplementary Table 2).
Among the 54 infant siblings with atypical development (but not
an ASD diagnosis) were the following phenotypic constellations:
ASD symptoms (n= 5), ASD symptoms with developmental,
language and/or adaptive behavior delay (n= 9); developmental
delay (n= 15), language delay (n= 10), language and adaptive
behavior delays (n= 5), deficits in adaptive behavior alone (n=
3), and attention deficit hyperactivity disorder (ADHD) symp-
toms or externalizing behaviors (n= 7). Of the 30 families with 2
or more infant siblings, 23 had 1 or more assessed as having ASD
and/or atypical development and 7 had all sibs typically
developing at age 3. The male:female ratio was 3.7:1 for ASD-
affected infant siblings, 1.6:1 for atypically developing siblings,
and 1.2:1 for non-ASD infant siblings.
Genomic findings in probands and infant siblings. From 253
probands, we identified 15 CNVs (in 13 individuals; 5.1%) that
were deemed ASD-relevant (see Methods; Supplementary
Tables 3 and 4). Where inheritance could be ascertained, 6 CNVs
(in 5 probands) were de novo (3 deletions, 3 duplications) and 8
CNVs (5 deletions, 3 duplications) were inherited (7 maternally, 1
paternally). For proband 14-0152-001, inheritance was unknown,
as parental samples were unavailable. All 8 inherited variants
were shared with an infant sibling (Fig. 2), of whom 4 were
diagnosed with ASD (Fig. 3a) and 3 showed atypical development
without a formal ASD diagnosis (Fig. 3b).
Among the 288 infant siblings of the probands, 13 carried
ASD-relevant CNVs (Fig. 2), of which 6 were considered
pathogenic and 7 were clinically defined as variants of unknown
significance overlapping genes implicated in ASD. Five infant
siblings had ASD-relevant CNVs that were not shared with the
related probands; 2 had ASD, 2 were atypically developing, and 1
was typically developing (Fig. 3c, d). Of the 2 typically developing
children with ASD-relevant CNVs, 14-0376-004 (Fig. 3d) had a
610 kb deletion at 16p11.2 and 12-8115-004 (Fig. 3b) had a
(shared) 1.7 Mb duplication at 16p13.11. Their evaluations at age
36 months did not indicate any developmental delays or ASD
symptoms. Both variants are associated with recurrent and
variably expressed syndromes, often involving ASD12,25,26.
Overall, among siblings of ASD probands, we found ASD-
related CNVs in 6 of 103 with ASD at age 3 years, in 5 of 54 with
atypical development, and in 2 of 131 with neurotypical
development. Four children (Fig. 3) who did not meet study
inclusion criteria had ASD-related CNVs deemed to be
pathogenic. Using only CNVs considered to be pathogenic or
likely pathogenic18,27, among infant siblings the positive
predictive values (PPVs) of these variants were 0.50 for ASD
and 0.83 for combined ASD/atypical development. Other
predictive statistics are shown in Table 1.
Whole-genome sequences (WGS) were available from 91
families of our cohort. We identified no additional ASD-
relevant CNVs, and of the potentially interesting sequence-level
variants (Supplementary Table 5), none were found in families
with previously recognized ASD-relevant CNVs (Supplementary
Fig. 1).
This study adds to growing evidence that specific biomarkers
might contribute to pre-symptomatic detection of infants likely to
develop ASD or other developmental disorders, at least from
sibships that include an ASD proband. Eleven of 157 siblings who
developed ASD or were atypically developing at age 3 carried a
CNV worthy of clinical follow-up (either inherited or de novo), 5
(3.2%) carried a pathogenic/likely pathogenic CNV and 6 (3.8%)
carried a variant of unknown significance (VUS).
Of the 7 total VUSs overlapping a gene associated with
a neuropsychiatric disorder, 6 were in siblings with ASD or
atypical development, with none in neurotypical children, despite
nearly equal numbers in each subgroup. Although not reported as
pathogenic in a clinical setting, VUSs involving ASD-relevant
genes may nonetheless be contributing factors for ASD or atypical
development, and of interest to families14,22. Two of 131 typically
developing siblings had CNVs considered as VUS or likely
pathogenic. These CNVs at 16p11.2 or 16p13.11 have frequencies
in the general population that range from 0.03 to 0.04% and 0.15
to 0.25%28–30 and have been associated with reduced
cognitive and general functioning28,31 and adult-onset pheno-
types32, respectively.
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To further assess the predictive impact of ASD-relevant CNVs in
a larger cohort, we analyzed published data from 2110 families from
the Simons Simplex Collection (SSC). This cohort differs from the
BRSC in being a quartet design with 4214 parents, 2124 ASD-
affected probands and 2423 ASD-unaffected children, assembled to
study de novo variants (single-point phenotyping; average age of
diagnosis 8.9 (±3.5) years for males and 9.11 (±3.7) for females;
6.6:1 male to female ratio for probands)33. Of the SSC “unaffected”
sibs, applying similar criteria as for the BSRC cohort revealed 288
(11.9%) with atypical behavioral and developmental profiles: 33
were suspected to have elevated ASD traits (Social Responsiveness
Scale-Parent Report Total T-Score > 6034); 139 had emotional and
behavioral problems (Child Behavioral Checklist-Parent Report
Total Problems T-Score > 6035); 65 displayed mild-moderate
R
ec
ru
itm
en
t a
nd
 c
lin
ica
l e
va
lu
at
io
ns
ASD
Atypically
developing 
 
Typically
developing  
35.8%
(n = 103)
18.8%
(n = 54)
45.5%
(n = 131)
Genotyped on
Affymetrix CytoScanTM HD
2 million copy number probes + 750,000 SNP probes 
 
G
en
ot
yp
in
g 
an
d 
CN
V
ca
llin
g 
R
es
ul
ts
 re
le
va
nt
 to
 A
SD
Detection of 1156 stringent, rare and exonic CNVs in probands,
siblings and parents
(see Supplementary Data File 2)
Genotype-phenotype correlation
(see Fig. 2)
Predictive value of chromosomal microarray in ASD diagnosis
(see Table 1) 
CNV QC and characterization
(see Methods)
253 families with a proband and ≥ 1 infant sibling
30 families had ≥ 2 infant siblings    
Phenotype 288 infant siblings in the formal infant siblings cohort
(age ∼ 3 years)  
 
ASD-relevant CNVs
Polygenic risk score analysis
91 of 253 families (118 infant siblings)
were also whole genome sequenced 
Further assessment of predictive value of chromosomal microarray in Simons
Simplex Collection (2110 ASD-affected families)
(see Supplementary Table 7)  
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adaptive behavior deficits (Vineland Adaptive Behavior Scales,
Adaptive Behavior Composite36 < 85); 51 met criteria in more than
1 category. While blinded to proband and sibling status, we
searched for ASD-relevant CNVs with the same classification
criteria used for the BSRC (see Methods).
We found 118 ASD-relevant CNVs in 116 of 2124 probands
(5.5%; 72.0% (85) pathogenic/likely pathogenic and 28.0% (33)
VUS) and 64 CNVs in 63 of 2423 unaffected sibs (2.6%; 34.4%
(22) pathogenic/likely pathogenic and 65.6% (42) VUS) (Supple-
mentary Data File 1 and Supplementary Table 6). These results
are similar to those found in probands and unaffected sibs in the
BSRC cohort (5.1% and 3.8%, respectively). Seven (11.1%) of
these sibs with ASD-relevant CNVs were deemed atypically
developing. When considering pathogenic and likely pathogenic
variants across the SSC, the PPV for ASD was 0.79, and for ASD
or atypical development was 0.83 (Supplementary Table 7). From
the SSC cohort, we identified 47 CNVs impacting 8 of the genes/
loci harboring ASD-relevant CNVs in the siblings of the BSRC.
Thirty of these CNVs were carried by probands, 2 by atypically
developing sibs and 15 by unaffected sibs (Supplementary
Table 6). The percentage of ASD-relevant CNVs in unaffected
sibs in the SSC is similar to that observed in unaffected sibs in the
BSRC. Furthermore, data analyzed from both cohorts yielded
lower percentages of ASD-relevant variants in non-ASD sibs
compared with probands, while noting that select variants are
found in symptomatic carriers in the general population.
Polygenic transmission disequilibrium test. Recognizing emer-
ging evidence for the role of combinations of common genetic
variants in ASD susceptibility13 and their potential efficacy in
predicting ASD risk, we determined the contribution of polygenic
risk scores (PRS) to the phenotype in the BSRC cohort using the
polygenic transmission disequilibrium test13. In families for
which genotype data were available for both parents, probands
and at least 1 infant sibling, we observed a statistically significant
over-transmission of risk variants from parents to probands (n=
189, mean difference (cohort z-score based)= 0.13, p= 0.01).
There were non-significant differences of risk transmission for
unaffected siblings (n= 112, mean=−0.003, p= 0.97), atypically
developing siblings (n= 44, mean=−0.004, p= 0.97) and ASD-
affected siblings (n= 93, mean= 0.07, p= 0.27) (Supplementary
Fig. 2). Power to reject the null hypothesis (assuming the PRS
explained 2.45% of phenotypic variance37) was ~98% for the
proband (n= 189) and 56% for the affected sibling (n= 93). The
significant over-transmission of risk from parents to probands
suggested that common genetic variants may contribute to the
phenotype in the BSRC sample. This PRS analysis in the SSC
revealed a similar statistical trend. Using a paired Student’s t-test,
we observed a significant difference in risk of transmission for
SSC probands (n= 2118, mean= 0.547, p < 1e-10) and a non-
significant risk of transmission for unaffected sibs (n= 2130,
mean=−0.021, p= 0.116) and atypically developing sibs (n=
286, mean=−0.012, p= 0.744).
Fig. 1 Project flowchart. Families consisting of a proband and at least 1 infant sibling were recruited through the Baby Siblings Research Consortium. The
proband was the first in the family to receive an ASD diagnosis. Psychometric data were collected for all siblings at ~36 months of age, at which point an
ASD diagnosis was made if the child met clinical criteria (see Methods). All children were also assessed for ASD, cognitive and adaptive behavioral
functioning at least once prior to the 36-month time point. We genotyped individuals from 253 families on the Affymetrix CytoScanTM HD Array and
whole-genome sequenced 91 of these families using established pipelines12–14. Copy number variants determined to be ASD-relevant were confirmed with
secondary methods. We scrutinized the phenotypes of high-risk infant siblings carrying these ASD-relevant CNVs to determine whether they (i) had ASD,
(ii) were atypically developing, or (iii) were neurotypical/non-ASD. There were also 34 siblings who did not meet criteria for formal enrollment but for
whom phenotype and microarray data were available. Following the general BSRC strategy, a separate CNV analysis was conducted on 2124 probands and
2423 non-ASD sibs from 2110 ASD-affected families part of the Simons Simplex Collection. Fourteen probands were monozygotic twins. Of the unaffected
sibs, 288 were atypically developing. This analysis was performed to further assess the predictive value of chromosomal microarray. ASD autism spectrum
disorder, CNV copy number variation.
CNVs found in 13/288
infant siblings (4.5%) 
8/288 (2.8%)
(see Fig. 3, panels a & b)
5/288 (1.7%)
(see Fig. 3, panels c & d) 
4 ASD 3 atypically developing
(non-ASD) 
2 ASD 1 typically developing
(16p11.2, 610 kb loss)
1 typically developing
(16p13.11, 1.7 Mb gain)
CNVs found in
18/253 families (7.1%) 
2 atypically developing
(non-ASD) 
CNV shared with proband CNV not shared with proband
Fig. 2 ASD-relevant CNVs among infant siblings (n= 288). Summary of ASD-relevant genetic findings in the infant sibling cohort, stratified by family
segregation and infant sibling phenotype. ASD autism spectrum disorder, CNV copy number variation.
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Legend
Fig. 3 Pedigrees demonstrating ASD-relevant CNVs in infant siblings. a Infant siblings with ASD who shared a CNV with a related index case (arrow).
Targeted testing (only) for a pathogenic CNV was performed on sibling 12-8257-005. b Atypically developing infant siblings who shared a CNV with a
related index case. Female sibling 4-0062-004 was positive for ASD on the ADOS (24 and 36 months) assessments, but subthreshold on the ADI-R.
Clinical impression was that the child did not have ASD. She had subthreshold scores on the MSEL Early Learning Composite (ELC) (SS= 76) and VABS
Adaptive Behavior Composite (ABC) (SS= 84). In family 1-0616, the second-born son (1-0616-004) displayed subthreshold ASD symptoms,
vulnerabilities in language and verbal reasoning, gross and fine-motor skill delay; the third-born son (1-616-005) (not in the official cohort) experienced
fine-motor delay as seen on the VABS at 24 months, and parents reported concerns regarding socialization. In family 4-0027, the female sibling displayed
behavioral rigidity and transition difficulties. The male sibling in family 12-8115 was developing typically. c Infant siblings with ASD who did not share a CNV
with a related index case. d Infant siblings with a CNV not shared with a related index case. Individual 4-0061-004 had language delay and cognitive
regression (ELC= 56). Male sibling 12-4453-005 scored just above threshold on the ADOS (CSS= 5), but the clinical history was not consistent with a
diagnosis of ASD. His ELC (SS= 88), and ABC (SS= 90) scores were within 1 standard deviation of the expected mean. The scores of male 14-0376-001
on the ADOS (CSS= 1), MSEL (ELC= 91) and the VABS (ABC= 105) reflected a typical developmental trajectory. Figure includes 5 additional non-infant
siblings who were not counted as part of the formal cohort (dotted outline). CNV classification is provided in Supplementary Table 4. ASD autism
spectrum disorder, CNV copy number variation, ADOS Autism Diagnostic Observation Schedule, CSS calibrated severity score, ADI-R Autism Diagnostic
Interview-Revised, MSEL Mullen Scales of Early Learning, VABS Vineland Adaptive Behavior Scales, SS standard score.
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Discussion
Early identification of the CNVs described in this study could be
used to tailor recurrence risk estimates to individual families, with
potential for intensified surveillance for infants at increased
likelihood due to positive CNV findings. There is evidence that
infants as young as 7 months with subtle features of ASD could
benefit from tailored interventions23,38,39, but there are also also
recent negative trial data40,41.
This study had possible limitations. First, given the 37%
recurrence of ASD in our BSRC families, compared with
6.9–19.5% found previously2–5, this cohort had selective over-
recruitment of infant siblings with ASD. A similar over-
recruitment was noted for atypically developing sibs, which
partially accounts for the difference in rate between cohorts
(29.2% in BSRC compared to 11.9% in SSC). This oversampling,
not uncommon in genetic studies, may bias estimates of positive
and negative predictive value of biomarkers. As well, PPV esti-
mates related to CNV detection must be considered relative to
overall ASD rates among participants. Further impacting the
predictive value statistics, we only considered diagnoses made by
3 years of age. Despite the stability of an ASD diagnosis at
36 months, clinical phenotypes are known to be fluid throughout
development and apparent non-ASD siblings might later
demonstrate ASD or another disorder as they age42,43. Likewise,
longitudinal studies following high-probability siblings from 3
years of age to middle childhood observed that an ASD diagnosis
was revoked in 5.6–20% of children44,45. Second, considering the
massive effort in phenotyping, the BSRC sample would be con-
sidered comparably large, but participants with ASD-relevant
CNVs were still few, limiting power of the analysis. The primary
BSRC study involved a cohort with increased probability of ASD,
and while the findings are generally consistent with those from
the SSC, other family structures may yield different findings.
The recurrent CNVs described here often display variable
expressivity and reduced penetrance for ASD, particularly when
sex is considered46. For these reasons, we explored inclusion of
siblings with atypical forms of ASD when determining PPV. We
attribute the low sensitivity (0.03 in BSRC) of these markers to
the vast heterogeneity in ASD etiology, but this parameter may
improve with clearer genotype-phenotype correlations17,47. We
can also consider coupling these already useful CNV indicators of
ASD with metrics captured by other genetic approaches such as
WGS and PRS discussed here, as well as other techniques, such as
brain imaging48 and other early phenotypic assessment49.
Families must receive adequate counseling when such variants
are found, at any stage of life, including the prenatal setting, so
that they fully understand the potential ramifications of these
findings. This sibling cohort also provided evidence for certain
CNVs as potential early biological predictors of ASD or other
developmental difficulties, whether or not they shared these with
their respective probands (Fig. 2), which will also influence
interpretation.
Methods
Subject recruitment and clinical evaluations. From 9 research sites registered
with the BSRC (The Center for Applied Genomics, Genetics, and Genome Biology,
The Hospital for Sick Children; Autism Research Center, Bloorview Research
Institute; Autism Research Center, IWK Health Center and Dalhousie University;
Department of Psychology, UC San Diego; Center for Autism and Related Dis-
orders, Kennedy Krieger Institute; Department of Psychology, University of Miami;
MIND Institute, Department of Psychiatry, UC Davis; Department of Psychology,
University of Washington; Vanderbilt Kennedy Center Treatment and Research
Institute for Autism Spectrum Disorders, Vanderbilt Kennedy Center; Autism
Research Center, University of Alberta), participants from 253 families enrolled
(134 from USA sites and 119 from Canada). Recruitment was through organiza-
tions serving individuals with ASD and their families, referrals from medical
professionals, web-based media, or word-of-mouth, as previously described2. This
study was approved by the Research Ethics Board (REB) at The Hospital for Sick
Children (REB # 0019980189) and informed consent was obtained from partici-
pants or their legal guardians, when appropriate. A total of 253 probands,
322 siblings (including 288 infant siblings), and 447 parents (242 mothers; 205
fathers) constituted the final cohort and were analyzed.
All families had at least 1 child (i.e., the proband) diagnosed with ASD
according to the Diagnostic and Statistical Manual for Mental Disorders, 4th
Edition (DSM-IV). We excluded probands with a genetic syndrome that could
account for their ASD (e.g., Fragile-X, Rett Syndrome)50. Younger siblings were
recruited at a mean age of 10.2 ± 8.4 months; we followed them, and determined
their clinical outcomes with respect to ASD at a mean age of 37.4 ± 2.3 months. An
expert clinician determined diagnostic status by clinical best-estimate, informed by
the Autism Diagnostic Observation Schedule (ADOS) (calibrated severity score
(CSS) ≥ 4 as threshold)51, DSM-IV criteria, psychometric assessment of language
and cognitive development (Mullen Scales of Early Learning (MSEL)52), adaptive
functioning (Vineland Adaptive Behavioral Scales (VABS)36), and overall clinical
impression.
Adapting criteria from published reports of this cohort6, from among infant
siblings not diagnosed with ASD, we defined another subgroup as “atypically
developing”. This classification was based on the presence of elevated ASD
symptoms (CSS ≥ 3, requisite scores on the Autism Diagnostic Index-Revised and
clinical impression), developmental delay (MSEL composite score > 1 SD below the
mean), language delay (MSEL expressive and/or receptive language subscale score
> 1 SD below the mean), deficits in adaptive behavior (VABS composite score or
subscale score > 1 SD below the mean) or other atypical behavior patterns (e.g.,
externalizing behaviors) or disorders (e.g., ADHD), as indicated by the clinician
best-estimate diagnoses and/or scores above cutoff.
From 253 families, 144 mothers and 127 fathers self-reported the Broader
Autism Phenotype Questionnaire (BAPQ) (Supplementary Table 8). The BAPQ
Table 1 Predictive statistics of microarray findings in infant siblings of ASD probands.
ASD (all ASD-
relevant CNVs)
ASD or atypical development
(all ASD-relevant CNVs)
ASD
(excluding VUS)
ASD or atypical
development (excluding VUS)
Statistic
Sensitivity (0.95 CI) 0.06 (0.02–0.12) 0.07 (0.04–0.12) 0.03 (0.01–0.08) 0.03 (0.01–0.07)
Specificity (0.95 CI) 0.96 (0.92–0.98) 0.98 (0.95–1.00) 0.98 (0.95–1.00) 0.99 (0.96–1.00)
Positive predictive value (0.95 CI) 0.46 (0.19–0.75) 0.85 (0.55–0.98) 0.50 (0.12–0.88) 0.83 (0.36–1.00)
Negative predictive value (0.95 CI) 0.65 (0.59–0.70) 0.47 (0.41–0.53) 0.65 (0.59–0.70) 0.46 (0.40–0.52)
Genotype/phenotype
Condition + 103a 157b 103a 157b
CNV+/condition+ 6 11 3 5
CNV+/condition – 7 2 3 1
CNV –/condition – 178 129 182 130
CNV –/condition + 97 146 100 152
Total infant siblings 288 288 288 288
VUS variant of unknown significance
Genotype refers to the identification of ASD-relevant CNVs observed in infant siblings
aAffected sibs (n= 103)
bAffected sibs (n= 103)+ non-ASD sibs with atypical development (n= 54) (see “Subject recruitment and clinical evaluations” in Methods)
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includes items mapping onto 3 broader scales (Aloof, Rigid, and Pragmatic
Language), which comprise ASD-related subclinical traits previously reported in a
subset of parents. A cutoff of 3.15 was shown to optimize agreement with expert
clinical assessment of the Broader Autism Phenotype (BAP)53.
Baby Siblings Research Consortium (BSRC) sample collection. For microarray
analysis, biological samples were obtained from 251 probands, 321 siblings and 444
parents (241 mothers; 203 fathers) at their respective recruiting sites (total samples
= 1016). Blood samples from U.S. sites (n= 517) were submitted to the DNA and
Cell Repository at Rutgers University, and extracted DNA was subsequently sent to
The Center for Applied Genomics (TCAG). Genomic DNA used for genotyping on
microarray was extracted from whole blood (86.0%; 874/1016 samples), saliva
(0.4%; 4/1016), lymphoblastoid cell lines (10.4%;106/1016), or source undocu-
mented (3.1%; 32/1016).
Microarray genotyping quality control metrics. Genomic DNA samples were
processed on the high-density Affymetrix CytoScanTM HD microarray platform at
TCAG (2.67 million copy number markers) following protocols in our other
published studies10,17,18,54. Quality control thresholds were imposed, as specified
by the manufacturer: Waviness standard deviation (Waviness SD) ≤ 0.12; median
absolute pairwise difference (MAPD) ≤ 0.25; and single-nucleotide polymorphism
(SNP) quality control (SNP QC) ≥ 15.0. One father’s sample did not meet these
criteria, but the sample was retained in the analysis to help identify CNV segre-
gation. We used PLINK55 software to identify loss of heterozygosity (LOH) and
Mendelian inconsistencies using the 750,000 informative SNPs available on the
array. We observed Mendelian inconsistencies in 3 families, and eliminated them
from the study.
Variant detection and characterization. We detected CNVs using 4 algorithms:
Chromosome Analysis Suite (ChAS) (Affymetrix Inc., USA), iPattern56,
Nexus57, and Partek58. We sequentially applied a series of data constraints to
ascertain high-confidence, rare CNVs27. We considered only stringent CNVs,
called by ≥2 algorithms, at least 1 of which was ChAS or iPattern, for down-
stream analyses. CNVs on the X chromosome were called uniquely by ChAS and
iPattern. We eliminated all calls on the Y chromosome. We retained CNVs ≥ 15
kb in length and overlapping ≥10 consecutive probes to reduce the detection of
false-positive calls. They were then restricted to those in which ≤70% spanned a
segmental duplication and ≥75% of the variant was present in a copy number
stable region as previously defined59. We used a platform-matched control
dataset consisting of 873 individuals with no reported psychiatric history, from
the Ontario Populations Genomics Platform (OPGP)60, to classify CNVs as rare.
We considered a CNV as rare if it did not exceed 50% reciprocal overlap with a
CNV found in <0.1% of the control dataset. To corroborate a CNV’s status as
rare, we compared to an additional 4 unrelated control populations totaling 9978
individuals: the Collaborative Genetic Study of Nicotine Dependence
(COGEND)61 and KORA62, genotyped on the Illumina Omni 2.5 M; the SAGE
consortium controls63, Ontario Colorectal Cancer case-control study cohort64,65
and the Health, Aging, and Body Composition (Health ABC) Study66, genotyped
on the Illumina 1 M; the Ottawa Heart Institute controls67, and POPGEN68,
both genotyped on the Affymetrix 6.0 microarray. We sequenced whole genomes
of 84 probands, 118 infant siblings and 158 parents (86 mothers; 72 fathers),
from 91 families, using DNA from whole blood17.
We used criteria adapted from the American College of Medical Genetics
classification69 and an established annotation strategy14,18,70 to classify CNVs as
ASD-relevant and pathogenic, likely pathogenic or variant of unknown significance
(VUS). A CNV was considered pathogenic or likely pathogenic if (a) it was
associated with an established genomic disorder of which ASD is a characteristic
(e.g., 16p11.2 microdeletion), or (b) it overlapped a coding exon of a high-
confidence ASD-susceptibility gene (e.g., SHANK3; Supplementary Data File 3).
We considered whether the CNV overlapping the gene was de novo (pathogenic)
or inherited (likely pathogenic). Variants overlapping exons of long noncoding
RNA PTCHD1-AS71, and specific noncoding exons of the MBD5 gene72, which
constitute the critical region of 2q23.1 microdeletion syndrome, were retained in
the analysis. We further defined a class of VUS as ASD-relevant if they overlapped
exons of candidate ASD-susceptibility genes or related neuropsychiatric disorder
genes (Supplementary Data File 3) and had a frequency ~0.1% in the Database of
Genomic Variants. We assessed the efficacy of the variants so identified, as markers
for ASD or atypical phenotype status, using the epiR package in R73 to calculate
positive predictive value, negative predictive value, sensitivity and specificity. All
CNVs in infant siblings were classified while blinded to the phenotype status of the
individual.
Whole-genome sequence data were processed as previously described17. We
defined rare loss of function and de novo damaging missense variants as in Yuen
et al.10. We prioritized single-nucleotide variants and indels that overlapped genes
associated with ASD and other related neurodevelopment disorders, and
considered whether variants with similar transcriptional consequences were found
in other ASD cases.
Molecular validation and characterization of CNVs. The presence of de novo
and ASD-relevant CNVs was confirmed via real-time quantitative PCR (qPCR)
using the TaqMan© Copy Number Assay and SYBR® Green methods; all
experiments were conducted in triplicate. For SYBR® Green assays, an amplicon
90–140 base pairs in length was amplified using 2 sets of primers positioned ≥
500 bp from both reported breakpoints. A similar amplicon designed within the
FOXP2 locus served as a 2-copy control74. All TaqMan© Copy Number Assays
involved predesigned probes located in the gene of interest and RNaseP, which
served as an endogenous control. All experiments included both male and
female control samples (HapMap samples: NA10851 (male) and NA15510
(female)).
Simons Simplex Collection (SSC) to assess CNV false discovery. In order to
assess the possible false discovery for CNVs associated with ASD, we performed a
separate CNV analysis on 2110 families from the SSC33. This included 2107
mothers, 2107 fathers, 2124 ASD probands, and 2,425 siblings. Families were
recruited as previously described (Fischbach and Lord, 2010). Of the 2425 sibs,
2093 are designated unaffected. Of the remaining 332 siblings, 2 have ASD and
have thus been excluded from the analysis, leaving 2423 sibs unaffected by ASD
available for CNV analysis.
As we did for unaffected sibs in the BSRC cohort of infant siblings, we looked
for atypical developmental outcomes in these non-ASD sibs using the psychometric
tools available. We considered the potential presence of ASD traits using the Social
Responsiveness Scale (SRS)-Parent Report (n= 2298)34; mild-moderate
developmental delay by identifying adaptive behavior deficits using the VABS (n=
2368) and other emotional and behavioral concerns as identified through the Child
Behavioral Checklist (CBCL)-Parent Report35 (n= 448 for ages 1.5–5 test; n=
1833 for ages 6–18 test). To define atypical development, we applied a cutoff of >1
SD below the mean for the total scores for the SRS and the CBCL, expressed as T-
scores (i.e., T-scores > 60), and the Adaptive Behavior Composite from the VABS,
expressed as a standard score (i.e., scores < 85). Sibs had to meet this cutoff on at
least 1 of the 3 tests to qualify as atypically developing.
We received microarray intensity data in the form of .IDAT files for 8761
individuals genotyped on 3 different microarray platforms: 1246 on the Illumina
Human1Mv1; 3826 on the Illumina Human1M-Duov3; and 3689 on the Illumina
HumanOmni2.5–4v1. We called CNVs using the same pipeline as for the infant
sibling cohort, with the exception that the following 3 algorithms were employed,
as previously described:18 PennCNV75, QuantiSNP76, and iPattern. Stringent
CNVs were called by a minimum of 2 of these algorithms, with at least one being
iPattern. We applied criteria for filtering and prioritizing variants as described
above. CNVs were not molecularly characterized, as no DNA for this cohort was
available.
Polygenic transmission disequilibrium test. We analyzed the contribution of
common genetic variants to ASD risk for families from the infant sibling cohort for
which microarray data were available for the proband (n= 189), at least 1 infant
sib (n= 193) and both parents. We generated PRS using PRSice77 (clump-kb 250,
clump-p 1.000000, clump-r2 0.100000, info-base 0.9), using a p-value threshold of
0.1 as suggested by Grove et al.78 in Supplemental Fig. 4.4.1. In total, 246,607 SNPs
were included in both the SNP genotypes from the Affymetrix CytoScanTM HD
array and the iPSYCH-PGC_ASD_Nov2017 GWAS summary statistic file, with
9,112,386 variants, of which 17,362 were removed due to having an INFO score less
than 0.90. For the study genotypes, we began with 749,157 SNPs from the Affy-
metrix CytoScanTM HD array, removing 83,849 SNPs with a call rate >90% and
97,770 SNPs with minor allele frequency < 5%. Using PRSice, 87,215 genotype
array variants were removed (e.g., A- > T), with 228,151 intersecting the ASD
GWAS variants. A total of 52,923 SNPs remained after linkage disequlibrium-based
clumping, of which 11,401 met the specified p-value threshold, and were thus used
for PRS computation.
We performed the same analysis for 2104 families from the Simons Simplex
Collection. All families consisted of 2x parents (n= 2104 mothers; n= 2104
fathers), a proband (n= 2118) and at least 1 unaffected sibling (n= 2416). Using
identical criteria for inclusion of SNPs, 53,803 SNPs remained after linkage
disequilibrium-based clumping, and 11,161 SNPs were enriched for in cases versus
controls as per a p-value of 0.1, and therefore used for the generation of PRS.
Previous estimates for narrow-sense heritability (h2g) for ASD are varied,
depending on phenotype definition, study design, genotyping method, and other
factors. Estimates include 12%37, 52%79, and 83%80; we used h2g= 60% in the
power calculation. Power was calculated under the liability threshold model
assuming prevalence of ASD of 1.5%81.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All raw microarray data for 1016 individuals that were genotyped on the Affymetrix
CytoScanTM HD Array were submitted to dbGaP and can be accessed via a data access
committee using dbGaP accession number phs001876.v1.p1. Whole-genome sequence data
are accessible through the Autism Speaks MSSNG database (https://research.mss.ng).
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